Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Beraprost sodium is a stable and orally active prodrug of PGI2.
Description | Beraprost sodium is a stable and orally active prodrug of PGI2. |
In vitro | Beraprost sodium treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. |
In vivo | Beraprost sodium oral adminstration can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis. |
Molecular Weight | 420.481 |
Formula | C24H29NaO5 |
CAS No. | 496807-11-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (594.57 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Beraprost sodium 496807-11-5 Others inhibitor inhibit